DK1471871T3 - Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin - Google Patents

Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin

Info

Publication number
DK1471871T3
DK1471871T3 DK02724904T DK02724904T DK1471871T3 DK 1471871 T3 DK1471871 T3 DK 1471871T3 DK 02724904 T DK02724904 T DK 02724904T DK 02724904 T DK02724904 T DK 02724904T DK 1471871 T3 DK1471871 T3 DK 1471871T3
Authority
DK
Denmark
Prior art keywords
erythropoietin
treatment
neurological dysfunction
dysfunction including
fructopyranose sulfamates
Prior art date
Application number
DK02724904T
Other languages
Danish (da)
English (en)
Inventor
Salaman Carlos Plata
Virginia Smith-Swintosky
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of DK1471871T3 publication Critical patent/DK1471871T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
DK02724904T 2001-02-02 2002-01-24 Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin DK1471871T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26619401P 2001-02-02 2001-02-02
PCT/US2002/003096 WO2002064085A2 (en) 2001-02-02 2002-01-24 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin

Publications (1)

Publication Number Publication Date
DK1471871T3 true DK1471871T3 (da) 2007-09-17

Family

ID=23013568

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02724904T DK1471871T3 (da) 2001-02-02 2002-01-24 Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin

Country Status (17)

Country Link
US (2) US6908902B2 (ru)
EP (1) EP1471871B1 (ru)
JP (1) JP2005501801A (ru)
KR (1) KR100896971B1 (ru)
AT (1) ATE361089T1 (ru)
CA (1) CA2437333A1 (ru)
CY (1) CY1106733T1 (ru)
DE (1) DE60219961T8 (ru)
DK (1) DK1471871T3 (ru)
ES (1) ES2284858T3 (ru)
MX (1) MXPA03006952A (ru)
NO (1) NO20033440L (ru)
NZ (1) NZ548578A (ru)
PT (1) PT1471871E (ru)
RU (1) RU2317086C2 (ru)
WO (1) WO2002064085A2 (ru)
ZA (1) ZA200306818B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
MXPA03006952A (es) * 2001-02-02 2004-10-15 Johnson & Johnson Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina.
EP1423127A1 (en) * 2001-08-30 2004-06-02 Ortho-Mcneil Pharmaceutical, Inc. Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
JP2005534650A (ja) * 2002-06-11 2005-11-17 ザ バーナム インスティテュート エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用
US20030235576A1 (en) * 2002-06-15 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg New drug combinations for the treatment of ischaemic conditions
DE10226814A1 (de) * 2002-06-15 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände
WO2004026299A1 (en) * 2002-09-17 2004-04-01 Motac Neuroscience Limited Treatment of dyskinesia
EP1815854A1 (en) * 2002-09-17 2007-08-08 Motac Neuroscience Limited Treatment of dyskenesia
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
AT500929B1 (de) 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
WO2007020922A1 (ja) * 2005-08-17 2007-02-22 Chugai Seiyaku Kabushiki Kaisha 脳疾患の治療剤および予防剤
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
US7741446B2 (en) * 2006-08-18 2010-06-22 Armagen Technologies, Inc. Fusion antibodies that cross the blood-brain barrier in both directions
CA2686816A1 (en) 2007-01-16 2008-07-24 The Johns Hopkins University Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
EP2997976A1 (en) * 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
US20090291092A1 (en) * 2008-05-22 2009-11-26 Miller Guy M Treatment of mitochondrial diseases with an erythropoietin mimetic
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US9533055B2 (en) 2009-03-18 2017-01-03 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of IgG-decoy receptor fusion proteins
DK2485761T3 (da) 2009-10-09 2019-05-06 Armagen Inc Fremgangsmåder og sammensætninger til øgning af iduronat-2-sulfatase-aktivitet i CNS
JP6266529B2 (ja) 2011-12-02 2018-01-24 アーマジェン・インコーポレイテッドＡｒｍａｇｅｎ， Ｉｎｃ． Ｃｎｓにおけるアリールスルファターゼａ活性を増加するための方法および組成物
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
JP6055076B2 (ja) 2012-03-23 2016-12-27 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ シネフリン及びトピラマートを含む組み合わせ製品
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5242942A (en) 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
WO1995003034A1 (en) 1993-07-19 1995-02-02 Amgen Inc. Stabilization of aerosolized proteins
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
IL116085A (en) 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
AU3501697A (en) 1996-06-28 1998-01-21 Ortho Pharmaceutical Corporation Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of postischemic neurodegeneration
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
AU3908597A (en) 1996-08-02 1998-02-25 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
ATE341625T1 (de) 1997-07-23 2006-10-15 Roche Diagnostics Gmbh Herstellung von erythropoietin durch endogene genaktivierung mit viralen promotoren
ATE255634T1 (de) 1997-09-01 2003-12-15 Aventis Pharma Gmbh Rekombinantes humanes erythropoietin mit vorteilhaftem glykosylierungsmuster
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
AU775422B2 (en) 1998-06-15 2004-07-29 Gtc Biotherapeutics, Inc. Erythropoietin analog-human serum albumin fusion
CA2369095C (en) * 1999-04-08 2006-07-25 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
NZ514690A (en) * 1999-04-13 2004-07-30 Kenneth S Modulation of excitable tissue function by peripherally administered erythropoietin
MXPA03006952A (es) * 2001-02-02 2004-10-15 Johnson & Johnson Tratamiento de disfuncion neurologica que comprende sulfamatos de fructopiranosa y eritropoyetina.

Also Published As

Publication number Publication date
ES2284858T3 (es) 2007-11-16
EP1471871A2 (en) 2004-11-03
RU2003124059A (ru) 2005-01-27
US20020169109A1 (en) 2002-11-14
US6908902B2 (en) 2005-06-21
CY1106733T1 (el) 2012-05-23
MXPA03006952A (es) 2004-10-15
WO2002064085A2 (en) 2002-08-22
RU2317086C2 (ru) 2008-02-20
JP2005501801A (ja) 2005-01-20
EP1471871B1 (en) 2007-05-02
CA2437333A1 (en) 2002-08-22
DE60219961T2 (de) 2008-01-17
DE60219961D1 (de) 2007-06-14
DE60219961T8 (de) 2008-04-17
US20050261182A1 (en) 2005-11-24
NO20033440D0 (no) 2003-08-01
PT1471871E (pt) 2007-06-05
EP1471871A4 (en) 2005-11-09
ZA200306818B (en) 2005-02-23
KR20040011458A (ko) 2004-02-05
ATE361089T1 (de) 2007-05-15
NO20033440L (no) 2003-09-29
WO2002064085A3 (en) 2004-09-10
KR100896971B1 (ko) 2009-05-14
NZ548578A (en) 2008-03-28

Similar Documents

Publication Publication Date Title
DK1471871T3 (da) Behandling af neurologisk dysfunktion omfattende fructopyranosesulfamater og erytropoietin
MX231981B (es) Tratamiento de semillas con combinaciones de piretrinas/piretroides y clotianidina.
MXPA03003074A (es) Tratamiento para semilla con combinaciones de insecticidas
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
IS6806A (is) Samsetningar af lyfjum (t.d. klórprómasíni og pentamídíni) fyrir meðhöndlun á æxlistruflunum
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
MX238203B (es) Tratamiento de semillas con combinaciones de piretrinas, piretroides y tlametoxam.
DK1392292T3 (da) Pyranoindazoler og deres anvendelse til behandling af glaukom
ITBO20000453A0 (it) Apparecchiatura e procedimento per la sterilizzazione del terreno .
DK1383742T3 (da) Syntese og fremgangsmåder til anvendelse af tetrahydroindolonanaloge og derivater
AU2001222215A1 (en) Lumbago treating girdle
DE60200302D1 (de) Laseraugenbehandlungseinrichtung
DK1143917T3 (da) Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
NO20023944D0 (no) Blanding og metoder for behandling av epilepsi
ATE333439T1 (de) Pflanzenkläranlage
BR0103928B1 (pt) equipamento para tratamento de efluentes e estação para tratamento de efluentes.
ITRM20020308A1 (it) Apparecchiatura per trattamenti terapeutici, e relativo metodo.
FIU20010133U0 (fi) Jäteveden käsittelylaitteisto
FR2825913B1 (fr) Stimulateur central hydro-dynamogene des membres inferieurs
NO20014850L (no) CML-terapi
FI5249U1 (fi) Kantojenkäsittelylaitteisto
FI5282U1 (fi) Jäteveden puhdistamo
ES1050173Y (es) Medalla con calendario perfeccionada.
ES1039627Y (es) Juego educativo de sobremesa.